Verdezyne Signs R&D Agreement for Novel Enzymes Gene Development with Syngenta
CARLSBAD, Calif.--(BUSINESS WIRE)--Verdezyne, Inc., a synthetic biology company focused on the industrial biotechnology markets, today announced it has signed an agreement with Syngenta Biotechnology, Inc. Under the terms of the agreement, Verdezyne will synthesize novel genes, to be tested for optimized expression of enzymes in plants by Syngenta, using its unique technology platform.
"We are enthusiastic about applying Verdezyne's technology platform for a leading agribusiness company," said E. William Radany, Ph.D., President and Chief Executive Officer, Verdezyne. "This relationship is yet another example of the unique power of Verdezyne's core technology to optimize the expression of key enzymes for the biotechnology marketplace."
Verdezyne employs its biological expertise and proprietary advanced computational algorithms to design and synthesize novel gene libraries for engineering proteins, metabolic pathways, and microorganisms to manufacture platform chemicals and biofuels.
Financial details of the agreement were not disclosed.
About Verdezyne
Founded in 2005, Verdezyne, formerly known as CODA Genomics, is a privately-held company that integrates its proprietary core technologies to direct the evolution of novel metabolic pathways for cost effective commercial production of biofuels and platform chemicals. Investors in Verdezyne include OVP Venture Partners, Monitor Ventures, Tech Coast Angels and Life Science Angels. For more information on Verdezyne, visit www.verdezyne.com.